Effects of myristoylated pseudosubstrate protein kinase C peptide inhibitors on insulin secretion.
Harris
T E
TE
Physiology Group, King's College London, U.K.
Persaud
S J
SJ
Saermark
T
T
Jones
P M
PM
D000818:Animals; D005947:Glucose / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D007700:Kinetics; D019814:Myristic Acid; D009227:Myristic Acids / Q000378:metabolism*; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D051381:Rats; D013379:Substrate Specificity; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D007328:Insulin; D009227:Myristic Acids; D010446:Peptide Fragments; D019814:Myristic Acid; D011493:Protein Kinase C; D005947:Glucose; D013755:Tetradecanoylphorbol Acetate